The apparent reduction in adiponectin levels from baseline to the end of study in children with NAFLD enrolled in the intervention arm might have resulted from the slightly, but not significantly, younger age of these children when compared to controls at baseline (7.5 vs. 8.0 years). This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.